Combined OX40 ligation plus CTLA-4 blockade

Stefanie N. Linch,William L. Redmond
DOI: https://doi.org/10.4161/onci.28245
2014-03-01
OncoImmunology
Abstract:It is becoming clear that combination strategies will be necessary to augment cancer immunotherapy. We report that combination anti-OX40/anti-CTLA-4 mAb immunotherapy improves survival by enhancing effector T cell expansion and function, even while inducing Th2 cytokine production. Furthermore, IL-4 blockade in addition to combination therapy significantly improved anti-tumor efficacy.
What problem does this paper attempt to address?